INTRODUCTION {#sec1-1}
============

INFUSE (Medtronic, Memphis, TN, USA), a genetically engineered human bone morphogenetic protein-2, is utilized to perform both "on-label" and "off-label" spinal fusions. INFUSE, combined with a bovine Type I collagen carrier, and placed in a lumbar tapered fusion device (LT Cage), together constitute an "on-label" device approved by the Federal Drug Administration (FDA) for anterior lumbar interbody fusion (ALIF). Although we are all "aware" that INFUSE is frequently utilized in an "off-label" capacity (not FDA approved) to perform other types of spinal fusions, here we quantify the costs and frequency of such "off-label" use at one institution in 2010.

MATERIALS AND METHODS {#sec1-2}
=====================

In 2010, INFUSE was used in an "on-label" or "off-label" capacity in 177 spinal fusions at one institution. Patients averaged 53 years of age (range, 19--85 years), and included 84 females and 93 males. Of note, 20.9% of the patients were over 65 years old. Surgical procedures included anterior, posterior or 360-degree cervical, thoracic and/or lumbar fusions (with/without decompression).

RESULTS {#sec1-3}
=======

Of the 177 spinal fusions that utilized INFUSE, it was used "on-label" to perform seven ALIF. It was utilized "off-label" in the remaining 170 fusions. The "off-label" cervical fusions included seven operations from three operative categories \[[Table 1](#T1){ref-type="table"}\]. The \"off-label\" thoracic/lumbar fusions utilizing INFUSE included 163 operations from five operative categories \[[Table 1](#T1){ref-type="table"}\]. Most of the operations (156 cases) fell into three thoracic and/or lumbar categories: 59 posterior lumbar interbody fusions, 59 posterolateral thoracic/lumbar fusions and 38 transforaminal lumbar interbody fusions.

###### 

Categories of "off-label" spinal fusions utilizing INFUSE at one institution in 2010
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INFUSE was utilized "off-label" in 96% of the cases (170 of 177 patients) at a cost of \$4,547,822, whereas it was utilized "on-label" in only 4% of the cases (seven of 177 patients) at a cost of \$296,419. A total of 244 INFUSE packages were utilized in 177 cases for an average of 1.38 packages/case (range 1--4). The average cost of INFUSE per operation was \$26,752.

Second operations, not necessarily directly attributable to INFUSE, occurred in 32 (18.8%) of 170 patients undergoing "off-label" spinal fusions \[[Table 1](#T1){ref-type="table"}\]. Two of seven "on-label" ALIF utilizing INFUSE also required secondary surgery.

DISCUSSION {#sec1-4}
==========

We examined the use of INFUSE to perform spinal fusions in one institution during 1 year. Although INFUSE is only "marketed" by the company for "on-label" use, we found at our institution that 170 (96%) of 177 cases were performed "off-label" at a cost of \$4,547,822. In fact, only seven (4%) of 177 cases were performed "on label" for ALIF alone, at a cost of \$296,419. Of note, the average cost of INFUSE was \$26,752 per operation, while the average range of costs for alternative bone graft supplements (e.g., demineralized bone matrix and Beta TriCalcium Phosphate \[Vitoss: OrthoVita, Malvern, PA, USA\]) per operation would range from \$2,672 to \$4,000 (with overhead).

Although we cannot directly link the requirement for second spinal operations to the use of INFUSE in this study, other studies have done so.\[[@ref1]--[@ref6]\] In particular, these studies have suggested that INFUSE leads to higher rates of hematomas/seromas, neurological deficits, soft-tissue swelling, ectopic bone formation, and vertebral osteolysis. The reoperation rate of 18.2% in the current study was larger than that reported in most of these studies.

Future cost-benefit analyses comparing INFUSE to less-expensive bone graft expanders are warranted for both "on-label" and "off-label" use.
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